Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
Source: Pharmaceutical Technology, 2026-10-20. Third-party report, linked to its original publisher; IC360 has not independently verified it.
Buying the UK-based biotech will add a siRNA drug candidate with high sales potential to Merck’s portfolio.
Source: Pharmaceutical Technology, 2026-10-20. Third-party report, linked to its original publisher; IC360 has not independently verified it.
